23.6 C
Vientiane
Tuesday, August 26, 2025
spot_img
Home Blog Page 3

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach

SHANGHAI, Aug. 25, 2025 /PRNewswire/ — Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius’ revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8% YoY, maintaining a steady positive inflow. Overseas products profits surged over 200%. Cash inflows from BD agreements exceeded RMB 1 billion, surging 280% YoY. As the overseas sales volume of commercialized products continues to rise, the company expects significant growth in overseas revenue and profits for the full year of 2025, with strong momentum likely to continue into 2026. The company remains committed to reinforcing its strategic focus on innovation and globalisation, actively advancing its end-to-end ecosystem to drive sustainable R&D growth with robust growth momentum. During the reporting period, the company invested RMB995.4 million in R&D, with an increase of 21.3% YoY in expensed R&D expenditures, prioritizing preclinical development of differentiated innovative molecules and construction of core innovation platforms.

Up to date, Henlius has 6 products launched in China, 4 approved for marketing in overseas markets, benefiting over 850,000 patients and reaching about 60 markets in Asia, Europe, Latin America, North America and Oceania. Meanwhile, the company is expanding its innovation pipeline in disease areas like oncology and autoimmune, advancing a differentiated portfolio of potential best-in-class (BIC) and first-in-class (FIC) candidates.

Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said “2025 is a pivotal year for Henlius. It is the year we shift into Globalisation 2.0 and step up the pace of innovation. We’re strengthening our end-to-end ecosystem and driving overseas revenue growth with global value at scale. Meanwhile, our core innovative products have achieved significant milestones, with the next-generation of high-potential molecules underway. Looking ahead, Henlius will adhere to patient-centricity and accelerate the delivery of superior innovative treatment solutions.”

Globalisation 2.0: actively advancing the end-to-end ecosystem

In the first half of 2025, Henlius’ global growth engine was in full swing, with global product revenue exceeding RMB2.5568 billion, representing an increase of 3.1% YoY.  Several products are accelerating their expansion into international markets, further improving patient access to essential therapies.

The company’s core innovative product serplulimab (trade name: HANSIZHUANG in China, Hetronifly® in Europe), the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of small cell lung cancer (SCLC), has recorded a global sales revenue of RMB597.7million during the reporting period. The overseas market expansion of serplulimab has been accelerated in the first half of 2025. It has received approvals in the Europe, Singapore, Malaysia, the United Kingdom and India for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Additionally, it has been approved in Indonesia and Thailand for the treatment of squamous non-small cell lung cancer (sqNSCLC). To date, serplulimab has been successfully approved in nearly 40 countries and regions, covering nearly half of the world’s population. A head-to-head bridging trial of serplulimab versus first-line standard of care atezolizumab for ES-SCLC in the U.S will also complete patient enrolment soon. The company plans to submit the Biologics License Application (BLA) to the FDA in the first half of 2026.

Henlius’ core breast cancer product HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), the “China-developed” mAb biosimilar approved in China, the EU, and the U.S., has recorded a global sales revenue of RMB1.4442 billion in the first half of 2025. During the reporting period, HANQUYOU (trastuzumab) was newly approved in countries including Mexico, bringing its cumulative approvals to over 50 countries and regions worldwide. In the HER2-positive breast cancer segment, Henlius has sequentially combined HANQUYOU (trastuzumab) with HANNAIJIA (neratinib) for extended adjuvant therapy to reduce recurrence risk in early-stage patients. Meanwhile, Henlius’ independently developed pertuzumab biosimilar, HLX11, has been accepted for marketing applications by regulatory agencies in China, the U.S., and Europe, and is anticipated to receive approval in th U.S. during the second half of 2025. Focusing on the breast cancer field, Henlius continues to build a comprehensive innovative product portfolio — candidates including Henlius’ HLX78 (lasofoxifene), an investigational novel endocrine therapy, the company’s novel epitope anti-HER2 mAb HLX22, the next-gen innovative HER2 ADC HLX87, the KAT6A/B inhibitor HLX97 with BIC potential, and the LIV-1 ADC HLX41 are accelerating their research progress.

In more disease fields, HLX04-O, a recombinant anti-VEGF humanised mAb injection jointly developed by the company and Essex, for the treatment of wet age-related macular degeneration (wAMD) has been accepted for the New Drug Application (NDA) in China in August 2025. This is the company’s first ophthalmic product submitted for marketing approval. The marketing applications for the denosumab biosimilar HLX14, intended for the treatment of osteoporosis and other indications, have been accepted in the U.S., EU, and Canada, with expected approvals in the second half of 2025.

In the first half of the 2025, Henlius accelerated the expansion of its core products into major global markets through strategic collaboration, further enhancing the company’s international influence and commercial capabilities. The company has entered into agreement with Abbott, granting it exclusive or semi-exclusive licenses for the development and commercialization of four self-developed biosimilars and one innovative biologic in 69 emerging markets including Asia and Latin America. The company has granted Dr. Reddy’s exclusive rights to HLX15, an anti-CD38 mAb, covering a total of 43 countries and regions across the U.S. and Europe. Besides, the company has also entered into an exclusive commercialization and semi-exclusive development collaboration with Lotus for the anti-PD-1 antibody serplulimab in multiple indications in South Korea. Additionally, the company has signed a licensing agreement with Sandoz, granting exclusive commercialization rights for HLX13, an CTLA-4 inhibitor, in the U.S., EU, Japan, Canada, and Australia.

In the first half of 2025, leveraging the advanced technologies and extensive resources, the company continued to reinforce its integrated biopharmaceutical platform including R&D, clinical trials, manufacturing, quality management, regulatory affairs, and commercialization. Up to date, the company has submitted over 800 drug registrations, and received more than 600 approvals, covering multiple countries and regions including China, the U.S., the EU, Canada, Indonesia and Japan. It has also conducted MRCTs in the U.S., the EU, Southeast Asia, Japan and other countries and regions, accelerating the globalisation process of its products. During the reporting period, Henlius continues to optimize its production operations and quality management system. The Songjiang Site has once again received the EU GMP Certificate, issued by the Federal Agency for Medicines and Health Products in Belgium, in July 2025. The completion of the Phase 1 of Songjiang Site II in August 2025 has further enhanced the company’s production capabilities. Up to now, the company has delivered over 1,150 batches of commercial GMP production, ensuring stable supply to countries and regions including China, Southeast Asia, Europe and Latin America. The company has successfully passed nearly 100 on-site inspections and audits conducted by global regulatory authorities and business partners, and has obtained GMP certifications from China, the EU, the U.S. and multiple PIC/S member countries, including Indonesia and Brazil.

Innovation breaks through the growth ceiling

In the first half of 2025, the company continued to advance its innovation-driven strategy, accelerating breakthroughs in cutting-edge technology platforms and driving robust growth in its innovative pipeline. Core products such as HLX43, HLX22, and serplulimab have each achieved significant global milestones.

HLX43 is a broad-spectrum anti-tumor ADC candidate targeting PD-L1 with BIC potential. The results of the phase 1 clinical trial of HLX43 have been first released at the 2025 ASCO Annual Meeting, demonstrating manageable safety profile and encouraging efficacy in various solid tumors especially in patients with NSCLC and thymic squamous cell carcinoma (TSCC). It shows encouraging efficacy in squamous and non-squamous NSCLC patients (sqNSCLC and nsqNSCLC), patients with or without EGFR mutation, patients with or without brain/liver metastasis, and PD-L1 positive or negative NSCLC patients, indicating its biomarker-independent antitumor potential. Previously, HLX43 has already been approved to conduct phase 2 MRCT in patients with non-small cell lung cancer (NSCLC) in China, the U.S., Japan and Australia, with first patients successfully dosed in both China and the U.S. Simultaneously, as the world’s first PD-L1 ADC indicated for thymic carcinoma (TC), HLX43 has received clinical trial approvals for the indication in the U.S. and other regions. A MRCT is planned to be initiated, aiming to fill the therapeutic gap in ADC treatment for this aggressive cancer type. In addition, the company is also accelerating the phase 2 clinical development of HLX43 in various solid tumors, including cervical cancer (CC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal cancer (NPC), colorectal cancer (CRC) and gastric/gastroesophageal junction cancer (GC/GEJC). Both monotherapy and combination therapies of HLX43 with other products are ongoing simultaneously to further exploit the synergistic effects of ADC-mediated cytotoxicity and immunotherapy-induced immune activation.

A phase 3 head-to-head clinical trial of Henlius’ novel enpitope anti-HER2 mAb HLX22 in combination with trastuzumab and chemotherapy comparing to current first-line standard of care therapy (trastuzumab + chemotherapy ± pembrolizumab) is steadily progressing. The first patient dosing has been completed in China, the U.S., Japan, Australia, and Korea, regardless of PD-L1 expression, with the aim of overcoming current limitations in first-line treatment of HER2-positive metastatic gastric cancer. Meanwhile, HLX22 has received Orphan Drug Designations from both the U.S Food and Drug Administration (FDA) and the European Commission (EC) in the first half the year for the treatment of gastric cancer, suggesting its significant therapeutic potential. Moreover, the updated data with over two years of follow-up from the phase 2 clinical study (HLX22-GC-201) evaluating HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive advanced gastric cancer were presented at the 2025 ASCO Annual Meeting. The study data demonstrated that the efficacy benefit of HLX22 in HER2-positive gastric cancer remained stable with extended follow-up, outperforming previous data and providing solid data foundation for the subsequent phase 3 study.

Focusing on lung and gastrointestinal cancer, Henlius is continuously advancing the global clinical development of its self-developed innovative anti-PD-1 mAb serplulimab. In the field of lung cancers, the U.S. and Japanese bridging trial of serplulimab for SCLC, and a phase 3 MRCT of serplulimab combined with chemotherapy and radiotherapy for limited-stage SCLC (LS-SCLC) are currently underway in parallel to establish a solid foundation for future overseas regulatory registration, among which the phase 3 MRCT in LS-SCLC has completed the subject enrollment. In the field of gastrointestinal cancers, a phase 3 clinical trial of serplulimab plus chemotherapy as neoadjuvant/adjuvant therapy for gastric cancer, as well as the phase 3 MRCT (ASTRUM-015) of serplulimab in combination with bevacizumab and chemotherapy in first-line treatment of metastatic colorectal cancer (mCRC) have also completed subject enrollment. During the reporting period, a total of over 20 pivotal studies, investigator-initiated trials (IITs), and real-world studies (RWS) on serplulimab in the fields of lung cancer and gastrointestinal cancer were presented at major international academic conferences such as ASCO GI, ELCC, IGCC, ASCO, and WCLC, and were published in scientific journals including Cancer Immunology, Immunotherapy and Cancer Communications. Among them, the end-of-study analysis of the phase 3 clinical trial (ASTRUM-005) of serplulimab as the first line treatment for ES-SCLC has been first released at the 2025 ASCO Annual Meeting, featuring a four-year OS data of 21.9% and thus validating its long-term survival benefit.

While fully leveraging the value of its flagship molecules, the company is actively addressing unmet clinical needs and building an early-stage pipeline of high-potential candidates, creating strong momentum for sustainable, high-quality growth over the medium to long term. During the period, the company continued building and optimizing its competitive R&D platforms, including its ADC platform Hanjugator™ with independent intellectual property, T cell Engager (TCE) platforms, the one-stop drug discovery platform HAI Club, and the independently developed computing platform HAI PBD to enhance R&D capabilities. Meanwhile, building on its core antibody expertise, the company is making ongoing breakthroughs across target coverage and molecular diversity, accelerating multiple candidates toward clinical development, including the potential FIC human sialidase enzyme therapeutic HLX79, HLX701, the novel anti-CD47 SIRPα-Fc fusion protein with good safety profile, anti-PD-L1/VEGF bispecific antibody (BsAb) HLX37, potential BIC KAT6A/B small molecule inhibitor HLX97, TCE platform-derived DLL3xCD3xCD28 TCE HLX3901 and STEAP1xCD3xCD28 TCE HLX3902, Hanjugator™-based EGFRxcMET ADC HLX48, and potential FIC B7H3-sialidase enzyme HLX316.

Looking ahead, Henlius will remain committed to its patient-centric mission, accelerate global expansion, drive the efficient implementation of innovation outcomes, and continuously enhance its global product supply as well as quality systems, aiming to bring more high-quality, affordable innovative treatment options to patients worldwide.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 6 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.

Galaxy Arena and TMElive Renew Strategic Partnership, Announcing Three Years of Expanded Events and a Commitment to Boosting Macau’s Development as the ‘City of Performances’


MACAU SAR – Media OutReach Newswire – 25 August 2025 – Galaxy Macau™’s world-class Galaxy Arena is proud to announce the renewal of its three-year strategic partnership with TMElive, extending its existing three-year run of its successful partnership. Under the newly extended agreement, both parties will continue supporting Macau’s quality development in culture and tourism and presenting multifaceted musical spectacles to music lovers, by leveraging shared resources and market-leading advantages.

Galaxy Arena celebrates the renewal of its strategic partnership agreement with TMElive for the next three years. Officiating guests at the agreement signing ceremony included from Galaxy Entertainment Group: Mr. Francis Lui, Chairman (3rd from right); Mr. Kevin Kelley, Chief Operating Officer – Macau (2nd from right); and Mr. Jeffrey Jiang, Executive Vice President, Entertainment Services (1st from right); and from Tencent Music Entertainment Group: Mr. Cussion Kar Shun Pang, Executive Chairman (3rd from left); Mr. Tsai Chun Pan, Group Vice President, President of Content Cooperation, Distribution and TMElive, and Head of TMEA and TIMA (2nd from left); Mr. Michael Tseng, Vice President of Content Cooperation Department.(1st from left).
Galaxy Arena celebrates the renewal of its strategic partnership agreement with TMElive for the next three years. Officiating guests at the agreement signing ceremony included from Galaxy Entertainment Group: Mr. Francis Lui, Chairman (3rd from right); Mr. Kevin Kelley, Chief Operating Officer – Macau (2nd from right); and Mr. Jeffrey Jiang, Executive Vice President, Entertainment Services (1st from right); and from Tencent Music Entertainment Group: Mr. Cussion Kar Shun Pang, Executive Chairman (3rd from left); Mr. Tsai Chun Pan, Group Vice President, President of Content Cooperation, Distribution and TMElive, and Head of TMEA and TIMA (2nd from left); Mr. Michael Tseng, Vice President of Content Cooperation Department.(1st from left).

From August 22 to 24, 2025, the two partners successfully hosted two flagship music events in Macau — the 2025 TMElive International Music Awards (TIMA), its standout debut edition, and the 2025 Tencent Music Entertainment Awards (TMEA), continuing its run of success with its sixth edition — drawing thousands of fans to Galaxy Arena and generating significant business opportunities for the surrounding community; delivering the effective realization of the “Tourism + Entertainment” concept to Macau.

Building on the collaboration’s initiation in 2023, the partnership has presented a variety of musical spectacles, drawing top-tier international entertainment to Macau. The cornerstone events of TIMA and TMEA have attracted top pop stars from Asia and the Pacific to Macau to engage in a series of musical keynote events, while receiving commendations for their contributions to the music industry. These musical extravaganzas have become tentpole annual events in the Macau calendar, underscoring its position as the “City of Performances”.

2025 TIMA continued its line-up of spectacular performances, presenting 25 groups of renowned artists from across the world, who worked their best to mesmerize the two audiences.
2025 TIMA continued its line-up of spectacular performances, presenting 25 groups of renowned artists from across the world, who worked their best to mesmerize the two audiences.

Thanks to the Strategic Partnership, A-list stars that have taken to the stage at Galaxy Arena including “King of K-pop” G-Dragon, who brought his world tour to Galaxy Arena in 2025. Thousands of fans gathered in Macau for these events, pushing forward the development of “Tourism + Entertainment” and fostering business opportunities for local independent operators, empowering Macau’s evolution to a diverse economy as the “City of Performances”.

Looking ahead, TIMA and TMEA will remain key highlights and a priority for Galaxy Arena under the renewed partnership, and the two parties are set to co-host a wider array of music performances – including large-scale concerts, music festivals, and celebratory ceremonies – leading to more immersive and culturally-focused galas. The renewed agreement will also facilitate more trademark performances. A new program will allow Tencent Music Entertainment Group’s online members to enjoy priority access to select, co-organized events. These initiatives aim to enrich Macau’s entertainment offerings, attract a broader audience, and raise the bar for live performance production in the region.

Held at the Galaxy Arena on August 24, 2025 TMEA commended artists and musicians for their outstanding contribution to the music industry with over 70 awards.
Held at the Galaxy Arena on August 24, 2025 TMEA commended artists and musicians for their outstanding contribution to the music industry with over 70 awards.

Mr. Francis Lui, Chairman of Galaxy Entertainment Group, commented: “Since opening in 2023, our 16,000-seat Galaxy Arena has become a favourite among show organizers, performers, and audiences alike. In the first half of 2025 alone, we hosted close to 190 events at Galaxy Arena and the adjacent Galaxy International Convention Center, welcoming thousands of attendees from around the world. We’re excited to continue our partnership with TMElive, which has proven to be a powerful driver of cultural exchange, tourism, and entertainment in Macau. Together, we’re moving closer to our vision of establishing Galaxy Macau as Asia’s leading entertainment hub, underscoring Macau’s important role as a ‘City of Performances’.'”

Mr. Cussion Kar Shun Pang, Executive Chairman of Tencent Music Entertainment Group, added: “TMElive has always been committed to delivering exceptional online and offline performance experiences. Since its inception, we’ve produced over 300 high-quality shows. The Tencent Music Entertainment Awards (TMEA) has grown into a globally recognized music event, beloved by fans and respected by industry professionals. This renewed partnership with Galaxy Arena will allow us to continue innovating and expanding the reach of Chinese music, both regionally and internationally.”

Thousands of Fans Celebrate Music in Macau: Tourism Meets Entertainment

From August 22 to 24, Galaxy Arena once again hosted the 2025 TIMA and 2025 TMEA, drawing music fans from across the region. The TIMA featured two nights of electrifying performances, from August 22-23, showcasing 25 groups of globally acclaimed artists.

The TMEA on August 24, themed “CHEERS FOR MUSIX” for its sixth edition, revealed the winners of over 70 awards, to compliment contributions in the areas such as music composition, vocals, and production. The 6th TMEA once again gathered top-tier stars from the circle, presenting well-established Chinese stars A2O MAY, CIIU, Yang Cao, Jolin Tsai, Accusefive, Young Dan, Higuchi Ai, Lars Huang, Jaylerr, Nathan Lee, Yu Liu, Yuning Liu, Yuxin Liu, MC Cheung, MIKA, NexT1DE, R.E.D, Soda Green, Supper Moment, YUQI, Jianci Tan, WeiBird, Qingfeng Wu, Silence Wang, Fiona Sit, Chen Yao, Jiayun Yu, Yisa Yu, Tia Ray, Pakho Chau, CHENLE, Junhao Zhang (SHUN), Jane Zhang, Shen Zhou (Names sorted in alphabetical order by family names), exuding an exciting vibe to the audience.

Bringing industry best practice to the fore, on August 23, Tencent Music Entertainment Group hosted the TME Chinese Music Impact Summit at Banyan Tree Macau, Galaxy Macau, with global music industry leaders converging to explore the future of Chinese and Asian music. Topics included future development strategies and how to elevate the Asian music industry on the global stage. The summit featured keynote speeches and collaborative discussions, both in-person and online, providing cutting-edge insights into the development of Chinese music.

Spanning over 3,000 square meters and accommodating up to 16,000 guests, as one of Asia’s largest and most advanced indoor arenas, Galaxy Arena, the venue for TIMA and TMEA, enjoys a design for world-class events. It provides flexibility for stage formation, allowing performers to fully express their music, style and creativity. It also supported Macau’s evolution as a “City of Performances” through this strategic partnership with TMElive. By delivering world-class entertainment to both international visitors and local residents alike, Galaxy Arena continues to underscore its peerless role as the ultimate setting for Macau’s “Tourism+” strategy; highlighting the city’s enduring cultural appeal as the ‘2025 Culture City of East Asia’.

Hashtag: #GalaxyMacau

The issuer is solely responsible for the content of this announcement.

ABOUT GALAXY MACAU INTEGRATED RESORT

Galaxy Macau™, The World-class Luxury Integrated Resort delivers the “Most Spectacular Entertainment and Leisure Destination in the World”. Developed at an investment of HK$43 billion, the property covers 1.1 million-square-meter of unique entertainment and leisure attractions that are unlike anything else in Macau. Eight award-winning world-class luxury hotels provide close to 5,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel, Raffles at Galaxy Macau, Andaz Macau. Unique to Galaxy Macau, the 75,000-square-meter Grand Resort Deck features the world’s longest Skytop Adventure Rapids at 575-meters, the largest Skytop Wave Pool with waves up to 1.5-meters high and 150-meters pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz- Carlton Spa, Macau help guests relax and rejuvenate.

As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies.

Embark on a delightful and rewarding journey at Galaxy Promenade, the one-stop shopping destination boasting some of the world’s most iconic luxury brands. Be the first to get the latest limited-edition items; explore fascinating pop-ups by coveted labels and revel in fabulous shopping rewards and privileges. Our VIPs are entitled to a highly-curated experience with dedicated personal shoppers at guests’ service, and be invited to exclusive luxury brand events. A different caliber of privileges and rewards also await. Discover the joys of fashion and stand at the forefront of style and sophistication—Galaxy Promenade has everything guests need to stay ahead of the style game.

Galaxy Cinemas takes immersive movie experiences to the next level with the latest audio-visual technology, ultra-luxurious facilities and bespoke services; CHINA ROUGE, one-of-a-kind cabaret lounge that evokes the glamor of Shanghai’s golden era with stylish entertainment and customizable surrounds; and Foot Hub, which presents the traditional art of reflexology for authentic relaxation and revitalization. For Authentic Macau Flavours and Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 Authentic Macau & Asian Flavours at Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events.

Meeting, incentive and banquet groups are also catered to with a portfolio of unique venues in Galaxy Macau and an expert service team. Galaxy International Convention Center (GICC) is the latest addition to the Group’s ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world-class event venue featuring 40,000-square-meters of total flexible MICE, and the 16,000-seat Galaxy Arena – the largest indoor arena in Macau.

For more details, please visit and

About TMElive

Launched in March 2023 by Tencent Music Entertainment Group, TMElive is brand that focuses on all-rounded live music performances and aims to create a professional, diverse, innovative and high-quality performance platform. Through interactive and innovative means, it strengthens the connection between established and emerging artists and their fans. Since its inception, it has presented over 300 online and offline music performances, providing fans with an immersive music and entertainment experience.

Lambda Builds AI Factories with Supermicro NVIDIA Blackwell GPU Server Clusters to Deliver Production-ready Next-Gen AI Infrastructure at Scale

  • Expanded AI infrastructure with faster results with Supermicro’s GPU-optimized servers
  • Large-scale AI factories for training and inference deployed in record time
  • Supermicro’s advanced liquid-cooling reduces power and cooling costs, enabling energy efficiency and sustainability

SAN JOSE, Calif., Aug. 25, 2025 /PRNewswire/ — Super Micro Computer, Inc. (SMCI), a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge, announced today that Lambda, the Superintelligence Cloud, has deployed a broad portfolio of Supermicro GPU-optimized servers including NVIDIA Blackwell based systems to expand its AI infrastructure and deliver high-performance systems to its customers. This collaboration first launched at Cologix’s COL4 ScalelogixSM data center in Columbus, Ohio, in June, offering the Midwest region access to enterprise-grade AI compute solutions.

Lambda Builds AI Factories with Supermicro and NVIDIA Blackwell GPUs
Lambda Builds AI Factories with Supermicro and NVIDIA Blackwell GPUs

“Supermicro is excited to collaborate with Lambda on powerful technology to push the boundaries of AI infrastructure,” said Vik Malyala, SVP, Technology & AI at Supermicro. “Our broad range of GPU-optimized servers enable leaders like Lambda to deliver powerful, flexible, and energy-efficient solutions that can handle demanding AI workloads.”

For more information about this collaboration, please visit https://www.supermicro.com/en/success-story/lambda 

To meet growing customer demands for high-performing servers, Lamba selected a mix of Supermicro systems including SYS-A21GE-NBRT with NVIDIA HGX B200, SYS-821GE with NVIDIA HGX H200 and SYS-221HE-TNR, all powered by the Intel®‘s Xeon® Scalable processors. A key highlight includes integration of Supermicro’s AI Supercluster with NVIDIA GB200 and GB300 NVL72 racks that can handle a massive training and inference workloads.

“Lambda is on a mission to accelerate the path to Superintelligence, building gigawatt-scale AI factories for training and inference for the world’s top AI labs, enterprises and hyperscalers,” said Ken Patchett, VP Data Center Infrastructure, Lambda. “As we strive to create infinite-scale compute for our customers, the depth of Supermicro’s server portfolio is a valuable asset for meeting our present and future needs.”

With these advancements, Lambda was successful in bringing online a large AI factory, new energy-efficient servers with advanced cooling technology, and a unique architecture that helps Lambda deploy large quantities of next-generation AI accelerators in record time.

Columbus is a fast-growing hub for AI innovation, from manufacturing to healthcare, and Cologix is proud to be the region’s leading colocation and interconnection provider,” said Chris Heinrich, Chief Revenue Officer of Cologix. “With multiple data centers interconnected by a diverse, high-capacity fiber ring and continued expansion planned, we’re building the digital backbone for AI and superintelligence. By combining Supermicro’s trusted systems, Lambda’s growing customer footprint and Cologix’s dense physical and virtual interconnection, enterprises across Columbus and the Midwest gain the low-latency access, scalability and performance needed to stay ahead.”

Together, Supermicro, Lambda and Cologix are enabling rapid AI development across the Midwest and in key industries such as healthcare, finance, manufacturing, retail, and logistics by offering the fastest path to production-ready AI and added flexibility to integrate with hyperscaler environments.

About Super Micro Computer, Inc.

Supermicro (NASDAQ: SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first-to-market innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure. We are a Total IT Solutions provider with server, AI, storage, IoT, switch systems, software, and support services. Supermicro’s motherboard, power, and chassis design expertise further enables our development and production, enabling next-generation innovation from cloud to edge for our global customers. Our products are designed and manufactured in-house (in the US, Asia, and the Netherlands), leveraging global operations for scale and efficiency and optimized to improve TCO and reduce environmental impact (Green Computing). The award-winning portfolio of Server Building Block Solutions® allows customers to optimize for their exact workload and application by selecting from a broad family of systems built from our flexible and reusable building blocks that support a comprehensive set of form factors, processors, memory, GPUs, storage, networking, power, and cooling solutions (air-conditioned, free air cooling or liquid cooling).

Supermicro, Server Building Block Solutions, and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.

All other brands, names, and trademarks are the property of their respective owners.

 

EcoFlow Unveils New Power Bank Lineups, Redefining How We Charge for Work, Travel and Life

RAPID Pro Series, RAPID Series and RAPID Mag Series offer on-the-go charging solutions for everyone, ranging from ultimate performance to ultra-slim, magnetic convenience

SEATTLE, Aug. 25, 2025 /PRNewswire/ — EcoFlow, a leading provider of eco-friendly power solutions, unveiled today three new series of power banks lines to meet the rigorous demands of its customers and the many ways they charge their lifestyles: RAPID Pro Series, RAPID Series and RAPID Mag Series.

RAPID Pro Series: Fast. Smart. Pro.

EcoFlow RAPID Pro Series represents the pinnacle of portable power innovation, built for professionals and tech-savvy users who demand speed, intelligence and versatility on the go.

RAPID Pro Series, RAPID Series and RAPID Mag Series offer on-the-go charging solutions for everyone, ranging from ultimate performance to ultra-slim, magnetic convenience
RAPID Pro Series, RAPID Series and RAPID Mag Series offer on-the-go charging solutions for everyone, ranging from ultimate performance to ultra-slim, magnetic convenience

RAPID Pro Power Bank (27650mAh, 300W, 140W Built-in Cable) is engineered for speed, safety and endurance. With EcoFlow’s signature X-Stream Technology, it offers industry-leading recharging — up to 80 percent in just 20 minutes using the 320W Desktop Charger via pogo-pin connection. The power bank supports up to 300W of multi-device output — simultaneously fast-charging laptops, phones, drones and even satellite internet devices.

Beyond performance, RAPID Pro 27K features a higher standard drone-grade battery core, lasting 300 cycles to 80 percent, and intelligent battery optimization through the EcoFlow App. With X-Guard thermal protection, a sensor monitors temperatures up to 10 million times per day, automatically halting operation when exceeding 118°F (48°C), ensuring safety in high-demand environments.

RAPID Pro X Power Bank (27650mAh, 300W) shares the same powerful core specs as the 27K, but its innovative modular design and customizable experience redefine the way mobile power banks interact with users.

Inspired by the concept of “1+X,” where “1” is the power bank and “X” represents an expandable set of magnetic accessories or replaceable cases, RAPID Pro X introduces an infinity ecosystem ranging from retractable cables to smartwatch chargers, all snapping on seamlessly to extend functionality. The replaceable cases let users match their device to their mood, workspace or travel style.

A standout 3.9-inch smart LCD screen provides real-time status updates of output. Users can personalize the display with custom images or even family photos. They can share their creations with others with the EcoFlow app, making power practical and personal.

Power for Every Moment and What’s Next

EcoFlow also offers the new-generation RAPID Series and RAPID Mag Series — versatile portable power banks designed to meet a wide range of everyday needs.

The RAPID Series strikes a perfect balance of speed, capacity (25k), and portability, offering single output options of 100W or 140W, making it ideal for fast, all-in-one charging on the go.

Meanwhile, the ultra-slim RAPID Mag Series is tailored for Apple users, delivering sleek, magnetic wireless charging in a compact form. Later this year, EcoFlow will introduce an upgraded version of the RAPID Mag power bank exclusively for the upcoming iPhone models. The version will achieve major breakthroughs in charging speed, energy efficiency and magnetic charging technology. Stay tuned for that launch.

The new RAPID Pro Series are more than power banks — it’s a versatile, personal energy companion for every moment of the day.
The new RAPID Pro Series are more than power banks — it’s a versatile, personal energy companion for every moment of the day.

“By integrating advanced technologies from our larger portable power stations, RAPID can offer pro-grade fast charging, safe operation and smart customization in an ultra-convenient form factor. It’s more than a power bank— it’s a versatile, personal energy companion for every moment of the day,” Essenmacher said.

Availability and Pricing

-Price (power bank only):

-RAPID Pro Power Bank (27650mAh, 300W, 140W Built-in Cable): $179.99 (USD).
-RAPID Pro X Power Bank (27650mAh, 300W): $249.99 (USD).

-More pricing and information about RAPID Series and other accessories can be found on EcoFlow website.

About EcoFlow

EcoFlow is a leading provider of eco-friendly energy solutions, committed to powering a new world. Since its founding in 2017, EcoFlow has aimed to be the FIRST in power solutions — Flexible, Innovative, Reliable, Simple, and Thorough — for individuals and families, whether at home, outdoors or on the go. With a smart manufacturing center in China, and headquarters in the USA, Germany and Japan, EcoFlow has empowered over 5 million users in 140 markets worldwide. For more information, visit https://www.ecoflow.com/us.

ICONSIAM and POP MART Unveil the World’s Most Stunning “POP MART GLOBAL LANDMARK STORE” in Thailand on the Iconic Chao Phraya River

Thailand’s newest global attraction elevates ICONSIAM’s standing as a premier Global Experiential Destination, offering fans rare access to exclusive collections and limited editions found nowhere else in the world.


BANGKOK, THAILAND – Media OutReach Newswire – 25 August 2025 – ICONSIAM, the global landmark along the Chao Phraya River, is once again redefining the retail and lifestyle landscapes, partnering with POP MART to create a new phenomenon along the Chao Phraya River — the newest POP MART GLOBAL LANDMARK STORE in Thailand and the world. Opening its doors on 8 August 2025, the store spans over 760 square meters on ICONSIAM’s 7th floor. Nestled in the breathtaking riverfront setting, it stands as a global hub of imagination, perfectly blending cutting-edge design with the rich charm of Thai culture. This landmark reaffirms its status as a Global Experiential Destination, delivering world-class experiences and captivating pop culture and art toy enthusiasts from around the world.

ICONSIAM and POP MART Unveil the World’s Most Stunning "POP MART GLOBAL LANDMARK STORE" in Thailand on the Iconic Chao Phraya River

A New Global Landmark for Art Toy Lovers

The design of the “POP MART GLOBAL LANDMARK STORE” has been conceived as a Window to the Fantasy, inviting visitors from around the world to step into the universe of POP MART in a way never experienced before. Spanning over 760 square meters, the space seamlessly blends Thai art and culture, modernity, and fantasy. It is the first Global Landmark Store to adopt an interior design concept deeply rooted in three distinctive aspects of Thainess: Water Culture, Traditional Thai Architecture, and Inclusiveness, under the brand philosophy of “Light up Passion and Bring Joy.” The entire space is designed with curves and circular forms, creating a sense of free-flowing movement, openness, and transparency, enriched by the interplay of light and reflective surfaces that flow endlessly — a design inspired by the Chao Phraya River, symbolizing both gentleness and strength, as well as Thailand’s charm and cultural diversity.

Another key highlight is the MOLLY: Thailand Landmark Store Limited Big Figure, a towering sculpture over four meters tall that stands proudly to welcome fans. Inspired by the travels of artist Kenny Wong, creator of the MOLLY character, the piece depicts MOLLY in an exquisitely elegant traditional Thai Chakkri dress, adorned with an intricately crafted royal headpiece topped with a fledgling bird — symbolizing new beginnings and hope. She is shown riding an elephant, a cherished symbol of Thailand. Surrounding her are many other iconic and beloved POP MART characters, warmly greeting every visitor who steps into the store. Fans can also discover a host of exclusive collections and limited editions available only at ICONSIAM, alongside iconic POP MART characters displayed throughout the store.

World’s First POP MART Café Outside China

Adding to the excitement, ICONSIAM introduces the world’s first POP MART Café outside of China. Each menu item is inspired by the brand’s beloved IP characters, offering a playful culinary experience that is as Instagram-worthy as it is delicious.

A special VIP Zone has also been created for exclusive occasions, featuring a signature Cotton Berry scent — a whimsical blend of cotton candy and wild berries, inspired by LABUBU Macaron. This delicate, sparkling fragrance is designed to evoke cherished childhood memories and create magical moments for every guest.

ICONSIAM Solidifies Its Status as a Global Landmark

A visionary joint venture between Siam Piwat, Charoen Pokphand Group (CP), and Magnolia Quality Development (MQDC), ICONSIAM is one of Thailand’s most celebrated achievements — where The Best of Thailand meets The Best of the World. Seamlessly blending art, heritage, innovation, and world-class architecture, it offers a retail and cultural experience unlike any other, setting new benchmarks for the future of global destinations.

Recognizing this unparalleled stature, POP MART’s decision to debut its most visually spectacular store in the world at ICONSIAM underscores the landmark’s unmatched reputation as a trusted partner for the world’s leading brands. With its unrivaled riverside location, awe-inspiring design, and ability to unite retail, culture, and tourism, ICONSIAM continues to redefine what it means to be a must-visit destination for travelers worldwide.

Now open on the banks of Thailand’s legendary Chao Phraya River, the POP MART GLOBAL LANDMARK STORE at ICONSIAM invites visitors to step into a vibrant world of creativity, joy, and imagination.

Hashtag: #SAWASDEEICONSIAM #ICONSIAM #POPMART #POPMARTTH #POPMARTTHAILAND

The issuer is solely responsible for the content of this announcement.

Everest Medicines Announces Participation in September Investor Conferences

SHANGHAI, Aug. 25, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer will be participating in person at investor conferences in New York City.

Morgan Stanley 23rd Annual Global Healthcare Conference

Date: Monday September 8, 2025

Format: Fireside chat and 1×1 meetings

Time: 5:35 p.m. ET

Location: New York, NY

H.C. Wainwright 27th Annual Global Investment Conference

Date: Wednesday, September 10, 2025

Format: In-person presentation and 1×1 meetings

Time: 8:00 a.m. ET

Location: New York, NY

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders.

For more information, please visit its website at www.everestmedicines.com.

 

Science and Technology Daily: Xi’an, Where Ancient Culture Meets Smart Future

XI’AN, China, Aug. 25, 2025 /PRNewswire/ — Xi’an in northwest China, where the ancient Silk Road began, now symbolizes China’s fusion of heritage and innovation. Part of our “Into Tech Park” series, this edition explores how technology fuels inclusive growth through the eyes of international students and entrepreneurs. Initiatives like the China-Europe Railway Express and Qinchuangyuan platform highlight Xi’an’s role as a global hub, where policy support and cultural openness turn ideas into real impact. Here, ambition finds a home, and the future is built on shared opportunity.

 

Xi’an, Where Ancient Culture Meets Smart Future

As war drums thundered across the theater, Ammara Hanif, a Pakistani student studying in Xi’an Jiaotong University (XJTU), gripped her seat. On the stage, through projection, dynamic lighting, holography, water screens and real-time video tracking, the production transformed history into a multisensory spectacle, reviving the grandeur of the Qin Dynasty and its legendary Terracotta Warriors. “This isn’t a history lesson,” she said. “It’s a time machine and we’re about to see where it leads.”

After the show, Anastassiya Yuy, a Kazakh student at the XJTU, said: “I never imagined technology could give history a heartbeat. This show didn’t just tell a story — it made me feel it. It showed that love and hope are universal, no matter where we’re from.”

Innovation for good

The combination of history and high-tech was just the beginning. The students were about to see how innovation is shaping the future beyond the stage.

The international visitors went to the Western China Science and Technology Innovation Harbor (iHarbour) of the XJTU. At its digital exhibition hall, they learned about the development history of the XJTU and its role in promoting international exchanges and sci-tech advancement.

At the Institute of Engineering & Medicine Interdisciplinary Studies, they learned about a four-year-old girl from Ganzi, Sichuan province in southwest China, who lost her nose in an accident. Thanks to 3D bioprinting and tissue engineering research led by Professor Wang Jing from the XJTU’s School of Mechanical Engineering, she received a new nose.

It was made possible through the Qinchuangyuan innovation platform, which links R&D, clinical application, and industrialization.

“This is medical treatment with a soul,” Yuy said. “I feel proud to study in a university that turns science into compassion.” Ammara added: “Seeing how interdisciplinary research can deliver real solutions gives me hope for the future.”

Furthermore, they engaged in in-depth discussions with Professor Li Min from the School of Mechanical Engineering. During the exchange, the visitors gained insights into cutting-edge interdisciplinary research focused on brain-computer interaction and rehabilitation.

At the School of Information and Communications Engineering, Professor Guo Cheng introduced millimeter-wave and terahertz microsystem technologies and their application in real-world settings.

The group also toured Building 7 at the iHarbour, a model of sustainable design that won the 2023 WFEO H.J. Sabbagh Prize for Excellence in Engineering Construction. Entirely designed by XJTU’s School of Human Settlements and Civil Engineering, the building has dual-layer solar photovoltaic-electrothermal systems, passive energy-saving strategies, and intelligent internal flow control, setting a new standard for eco-friendly smart architecture.

This forward-thinking mindset extends into education, where global partnerships are shaping the next generation of innovators. The students visited the XJTU-POLIMI Joint School, established in 2022. As the first Sino-foreign cooperative educational institution between Politecnico di Milano (POLIMI) and a Chinese university, the joint school serves as a global platform for education, research and startup incubation. “Education without borders,” said Russian student Alexey Pilipchak. “This is what global learning should be.”

Where openness fuels shared growth

Innovation thrives where ideas and intelligence flow freely. In Xi’an, this openness is embodied not just in factories and universities, but especially in the rails that connect them to the world.

At the Shaanxi Automobile Holding Group, the visitors gained an in-depth understanding of smart manufacturing. “In just few minutes, workers with technical support assembled an entire cabinet,” Ammara said. “The smart technology shows speed, efficiency and precision. It’s intelligent work.”

Emelyanova Anastasiya, a young entrepreneur from Belarus, was struck by the company’s customer service: “I’ve never heard of a company offering such comprehensive support. What you have done is to build long-term trust. Your service is exceptional.”

At the Xi’an International Port, a China-Europe Railway Express (Xi’an) train slowly pulled away, embarking on another journey along the bustling modern Silk Road. In the first half of 2025 alone, 3,055 such trains ran between Xi’an and different global destinations, carrying 3.45 million tons of cargo, a 34.8 percent year-on-year increase. “This is the new Silk Road,” remarked Shamsullah Shariati, a young entrepreneur from Afghanistan, adding that it means a lot for international cooperation. Yuy, who comes from Almaty, the largest city in Kazakhstan, said: “I used to think of borders as walls. Now I see them as connections. This train doesn’t just carry goods — it carries opportunity.”

Alexey, majoring in logistics management, said: “China is one of the world’s largest trading nations and also one of the fastest-developing countries in global logistics and transportation systems. I wanted to gain more knowledge and experience in this field, so I decided to come and study here.”

In ancient times, Xi’an served as a crucial eastern terminal of the Silk Road, a major trade route connecting the East and West. Today, it is regaining that legacy through innovation, collaboration and openness, demonstrating how technology and connectivity are shaping a future where both tradition and progress coexist harmoniously.

The city that makes foreigners feel at home

This spirit of openness is not just reshaping the city’s skyline. More importantly, it’s also creating new opportunities for people from around the world.

For Mukum Martin Mukum, a Cameroonian entrepreneur who has lived in Xi’an in northwest China for nine years, it was not the immigration officer’s stamp on his passport that made him feel at home, it was a cup of tea.

“It happened at a government event,” Mukum recalled during a recent interview. “I discovered a local tea so remarkable that I immediately sent some to my mother. Her response ‘Why didn’t you bring this home sooner?’ was my ‘aha’ moment. Now I’m determined to introduce this treasure to Cameroon and build a business around it.”

That spark of entrepreneurial idea, born from cultural exchange and supported by local policy, is exactly what the Xixian New Area of Xi’an is cultivating.

A national sci-tech innovation special zone, the Xixian New Area is a window to the Qinchuangyuan platform, where new ideas are born and academic strengths transform into economic impact.

Han Ping, deputy director of the technology innovation and new economy bureau of Xixian New Area, told Science and Technology Daily: “Xi’an is a city of knowledge, home to over 100 universities and top-tier research institutions. Qinchuangyuan was created to turn academic strength into real economic impact by opening doors to global talent and turning ideas into action.”

The Xixian New Area launched a pilot program to attract talent from around the globe. The process is simple: Submit a business plan and choose an international incubator. And upon approval, applicants can receive full support, from company registration and legal aid to work permits and office space.

“We want you to thrive,” Han said. Even students can participate. Through partnerships with universities like the Xi’an Jiaotong University (XJTU), they can intern with local firms, test market ideas, and gain real-world experience long before graduation. “It’s a bridge from campus to commerce,” Han added. “And it’s open to everyone.”

 

Xi’an, Where Ancient Culture Meets Smart Future
Xi’an, Where Ancient Culture Meets Smart Future

Recon Hits Milestone: Chemical Recycling Plant Construction Finished as Project Nears Production Launch

BEIJING, Aug. 25, 2025 /PRNewswire/ — Recon Technology Ltd. (“Recon” or “the Company”), a China-based provider of oilfield and low-carbon energy services, announced today that the main manufacturing plant for Shandong Recon Renewable Resources Technology Co., Ltd. (“Shandong Recon”)’s 40,000-ton-per-year waste plastic chemical recycling project (“Recon Plastic Chemical Recycling Project”) was successfully topped out. This marks a key breakthrough in the project’s construction, as it officially enters the equipment installation and commissioning phase. To date, the Company has invested over $15 million in this project. The project is expected to be fully completed by November 2025, and a required one-month trial operations production phase will commence in December 2025, in accordance with domestic regulatory laws, rules, and regulations.

Recon 40,000-ton-per-year waste plastic chemical recycling project
Recon 40,000-ton-per-year waste plastic chemical recycling project

The Recon Plastic Chemical Recycling Project spans an area of approximately 50 acres. Upon completion and commencement of operations, the main construction components of the project will include six pyrolysis units, two distillation units, and corresponding environmental protection facilities. The project is expected to produce 30,000 tons of plastic pyrolysis oil and 6,000 tons of carbon residue annually, generating an estimated $30 million in annual returns and achieving the high-value conversion of waste plastic resources.

Recon is currently engaged in in-depth discussions with several multinational chemical giants and leading domestic chemical companies. The Company has successfully signed product purchase intent and strategic cooperation agreements to jointly explore the diverse applications of its high-value pyrolysis oil products.

Technologically, the Recon Plastic Chemical Recycling Project adopts a dual-process approach combining catalytic pyrolysis and catalytic reforming. The pyrolysis process employs a “horizontal screw-type three-stage continuous reactor” for the first time, and effectively addressing the technical challenge of plastic coking in traditional processes and ensuring stable and continuous feedstock supply. Additionally, the introduction of catalytic reforming significantly increases the olefin content of the pyrolysis oil, substantially enhancing its value and competitiveness in the market. These technological breakthroughs are leading-edge applications in the global plastic pyrolysis field. Currently, the primary raw material for this project is membrane film-type waste plastic, which is difficult to process using physical recycling methods.

Management Commentary

Mr. Yin Shenping, the CEO of Recon, stated: “We are delighted to announce the successful completion of the main structures of the Shandong project, which marks an important milestone in its construction. This demonstrates our team’s ability to execute efficiently and underscores our commitment to advancing the industrialization of the plastic chemical recycling industry. Our core process has passed scientific and technological achievement evaluations by authoritative institutions, rigorous industrialization experiments, and domestic safety and reliability verification, laying a solid foundation for the project’s safe and stable operation.”

“During 2025, our primary objective is to ensure the project’s smooth commissioning and stable production of products that meet stringent standards. We will spare no effort to transform the Shandong Recon plant into a globally leading benchmark facility for the stable and continuous production of plastic chemical recycling. The plastic pyrolysis oil produced here will serve as high-quality, sustainable chemical feedstock for large-scale chemical plants and consumer goods companies both domestically and internationally. We are also striving to meet international certification requirements such as ISCC (International Sustainability and Carbon Certification).

“By implementing full-process digital management, we are actively building a low-carbon smart factory. This is not only to improve operational efficiency and environmental performance but also to establish a ‘standard factory’ model that can be rapidly replicated. This will support Recon’s future rapid scale expansion in the field of waste plastic resource utilization. We firmly believe that this project will be a significant source of profit for Recon upon its launch. Once operational, the project will effectively utilize the resources of various low-value waste plastics, including municipal solid waste plastics, industrial waste plastics, and agricultural films. This will provide a technical solution to address “white pollution” and promote a circular economy. In the future, Recon will continue to focus on upgrading core technologies for waste plastic chemical recycling, integrating and optimizing raw material supply chains, and expanding terminal product portfolios to build a more complete industrial ecosystem and achieve higher economic and social value.”

About Recon Technology, Ltd (“RCON”)

Recon Technology, Ltd (NASDAQ: RCON) is the People’s Republic of China’s first NASDAQ-listed non-state-owned oil and gas field service company. Recon supplies China’s largest oil exploration companies, Sinopec and The China National Petroleum Corporation (“CNPC”), with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measure for increasing petroleum extraction levels, reducing impurities and lowering production costs. Through the years, RCON has taken leading positions within several segmented markets of the oil and gas filed service industry. RCON also has developed stable long-term cooperation relationship with its major clients. For additional information please visit: http://www.recon.cn/

Forward-Looking Statements Disclaimer:

Recon includes “forward-looking statements” within the meaning of the federal securities laws throughout this press release. A reader can identify forward-looking statements because they are not limited to historical fact or they use words such as “scheduled,” “may,” “will,” “could,” “should,” “would,” “expect,” “believe,” “anticipate,” “project,” “plan,” “estimate,” “forecast,” “goal,” “objective,” “committed,” “intend,” “continue,” or “will likely result,” and similar expressions that concern Recon’s strategy, plans, intentions or beliefs about future occurrences or results. Forward-looking statements are subject to risks, uncertainties and other factors that may change at any time and may cause actual results to differ materially from those that Recon expected. Many of these statements are derived from Recon’s operating budgets and forecasts, which are based on many detailed assumptions that Recon believes are reasonable, or are based on various assumptions about certain plans, activities or events which we expect will or may occur in the future. However, it is very difficult to predict the effect of known factors, and Recon cannot anticipate all factors that could affect actual results that may be important to an investor. All forward-looking information should be evaluated in the context of these risks, uncertainties and other factors, including those factors disclosed under “Risk Factors” in Recon’s most recent Annual Report on Form 20-F and any subsequent half-year financial filings on Form 6-K filed with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by the cautionary statements that Recon makes from time to time in its SEC filings and public communications. Recon cannot assure the reader that it will realize the results or developments Recon anticipates, or, even if substantially realized, that they will result in the consequences or affect Recon or its operations in the way Recon expects. Forward-looking statements speak only as of the date made. Recon undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances arising after the date on which they were made, except as otherwise required by law. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included herein or that may be made elsewhere from time to time by, or on behalf of, Recon.

For more information, please contact:

Ms. Liu Jia

Chief Financial Officer

Recon Technology, Ltd

Phone: +86 (10) 8494-5799

Email: info@recon.cn